Dynavax Technologies Stock Price, News & Analysis (NASDAQ:DVAX)

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) issued its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.03. The biopharmaceutical company earned $8.30 million during the quarter, compared to analysts' expectations of $8.24 million. Dynavax Technologies had a negative net margin of 781.10% and a negative return on equity of 304.71%. The business's revenue was up 564.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.63) EPS. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Dynavax Technologies.

4 Wall Street analysts have issued 1-year target prices for Dynavax Technologies' shares. Their predictions range from $13.00 to $30.00. On average, they anticipate Dynavax Technologies' share price to reach $21.00 in the next year. This suggests a possible upside of 358.5% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

News headlines about DVAX stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dynavax Technologies earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Spectrum Pharmaceuticals (SPPI), Epizyme (EPZM), Zymeworks (ZYME), Dicerna Pharmaceuticals (DRNA), Amphastar Pharmaceuticals (AMPH), Esperion Therapeutics (ESPR), ArQule (ARQL), Amneal Pharmaceuticals (AMRX), Homology Medicines (FIXX), Axsome Therapeutics (AXSM), Odonate Therapeutics (ODT), TherapeuticsMD (TXMD) and Phibro Animal Health (PAHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), Kite Pharma (KITE), United Continental (UAL), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.01%), Senvest Management LLC (6.06%), Vanguard Group Inc. (5.53%), Chicago Capital LLC (4.51%), Eagle Asset Management Inc. (2.95%) and UBS Asset Management Americas Inc. (2.67%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., JPMorgan Chase & Co., Creative Planning, Bank of America Corp DE, A.R.T. Advisors LLC, Northern Trust Corp, Gables Capital Management Inc. and Bank of New York Mellon Corp. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, UBS Asset Management Americas Inc., Senvest Management LLC, Orbimed Advisors LLC, Point72 Asset Management L.P., C WorldWide Group Holding A S, Vanguard Group Inc. and Chicago Capital LLC. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $4.58.

Dynavax Technologies has a market capitalization of $298.41 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]